A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.
Paxlovid does not reduce long COVID risk in vaccinated individuals, study finds
- Post author:
- Post published:January 4, 2024
- Post category:uncategorized